1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Lonza Group AG
  6. News
  7. Summary
    LONN   CH0013841017

LONZA GROUP AG

(LONN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Lonza Posts Higher 2021 Sales; Confirms Mid-Term Targets

01/26/2022 | 01:50am EDT

By Cecilia Butini

Lonza Group AG on Wednesday posted higher sales for full-year 2021 and reconfirmed its mid-term guidance until 2024.

The Swiss life-sciences company said core earnings before interest, taxes, depreciation and amortization grew to 1.67 billion Swiss francs ($1.82 billion), from CHF1.38 billion the year prior, on sales that grew to CHF5.41 billion from CHF4.51 billion.

Reported Ebitda fell to CHF1.37 billion from CHF1.38 billion because of a provision the company took for the environmental remediation of a landfill, it said.

Net profit also declined, coming in at CHF677 million, compared with CHF732 million in 2020, it said.

The company said it expects low- to mid-teens sales growth at constant exchange rates in 2022. It also reconfirmed its 2024 mid-term targets, saying that it expects a core Ebitda margin in line with the mid-term guidance already this year.


Write to Cecilia Butini at cecilia.butini@wsj.com


(END) Dow Jones Newswires

01-26-22 0150ET

Stocks mentioned in the article
ChangeLast1st jan.
LONZA GROUP AG 0.04% 555 Delayed Quote.-27.15%
SWISS LIFE HOLDING AG -0.22% 547 Delayed Quote.-1.93%
All news about LONZA GROUP AG
08:10aLONZA : and Israel Biotech Fund Collaboration Framework Agreement to Support Biologics and..
PU
05/23Switzerland's Lonza to Scale Up Inhalation Capabilities at US Site
MT
05/23LONZA : to Expand Inhalation Capabilities at Tampa Site
PU
05/18Lonza Opens New Facility for Kodiak Sciences' Retinal Diseases Drug
MT
05/09Lonza, ALSA Ventures Partner To Support Development Of Small Molecule Drug Candidates
MT
05/09LONZA GROUP AG : Ex-dividend day for Distribution from share premium account
FA
05/09LONZA GROUP AG : Ex-dividend day for final dividend
FA
05/06EuroAPI gains on market debut after spin-off from Sanofi
RE
05/05LONZA GROUP AG : Proxy Statments
CO
05/05LONZA GROUP AG : Dividends
CO
More news
Analyst Recommendations on LONZA GROUP AG
More recommendations
Financials
Sales 2022 6 152 M 6 410 M 6 410 M
Net income 2022 1 064 M 1 108 M 1 108 M
Net cash 2022 423 M 441 M 441 M
P/E ratio 2022 38,7x
Yield 2022 0,59%
Capitalization 41 175 M 42 896 M 42 896 M
EV / Sales 2022 6,62x
EV / Sales 2023 5,90x
Nbr of Employees 16 218
Free-Float 98,6%
Chart LONZA GROUP AG
Duration : Period :
Lonza Group AG Technical Analysis Chart | LONN | CH0013841017 | MarketScreener
Technical analysis trends LONZA GROUP AG
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 20
Last Close Price 555,00 CHF
Average target price 796,79 CHF
Spread / Average Target 43,6%
EPS Revisions
Managers and Directors
Pierre-Alain Ruffieux Chief Executive Officer
Philippe Deecke Chief Financial Officer
Albert M. Baehny Chairman
Stefan Stoffel Head-Small Molecules Exclusive Synthesis Operation
Werner J. Bauer Independent Director
Sector and Competitors
1st jan.Capi. (M$)
LONZA GROUP AG-27.15%42 618
MODERNA, INC.-48.00%54 740
IQVIA HOLDINGS INC.-28.41%38 497
SEAGEN INC.-13.67%25 649
ICON PUBLIC LIMITED COMPANY-30.17%17 688
CELLTRION, INC.-26.77%16 131